223 related articles for article (PubMed ID: 29518460)
1. Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review.
Maloney NJ; Hisaw LD; Worswick S
J Am Acad Dermatol; 2018 Sep; 79(3):585-587. PubMed ID: 29518460
[No Abstract] [Full Text] [Related]
2. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation.
Maloney NJ; Hisaw LD; Worswick S
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 29034547
[TBL] [Abstract][Full Text] [Related]
3. Pityriasis rubra pilaris successfully treated with adalimumab.
Schreml S; Zeller V; Babilas P; Karrer S; Landthaler M; Szeimies RM
Clin Exp Dermatol; 2010 Oct; 35(7):792-3. PubMed ID: 20345992
[No Abstract] [Full Text] [Related]
4. Erythrodermic pityriasis rubra pilaris managed at home: intensive community care followed by ustekinumab.
Ismail N; Callander J; Williams M; Anstey AV
Clin Exp Dermatol; 2018 Aug; 43(6):749-751. PubMed ID: 29779249
[No Abstract] [Full Text] [Related]
5. Rapid and sustained remission of pityriasis rubra pilaris with adalimumab treatment.
O'Kane D; Devereux CE; Walsh MY; Hoey SE
Clin Exp Dermatol; 2010 Jun; 35(4):e155-6. PubMed ID: 19925485
[No Abstract] [Full Text] [Related]
6. Treatment of pityriasis rubra pilaris with ustekinumab.
Wohlrab J; Kreft B
Br J Dermatol; 2010 Sep; 163(3):655-6. PubMed ID: 20491761
[No Abstract] [Full Text] [Related]
7. Refractory pityriasis rubra pilaris with good response after treatment with ustekinumab.
Aragón-Miguel R; Prieto-Barrios M; Calleja-Algarra A; Velasco-Tamariz V; Andres-Lencina JJ; Ortiz-Romero P; Monsálvez-Honrubia V
J Dtsch Dermatol Ges; 2018 Aug; 16(8):1022-1025. PubMed ID: 29947473
[No Abstract] [Full Text] [Related]
8. Should ustekinumab really be used as first-line biological therapy in pityriasis rubra pilaris?
Balestri R; Bardazzi F; Antonucci A
Br J Dermatol; 2010 Oct; 163(4):896-7; author reply 897-8. PubMed ID: 20662839
[No Abstract] [Full Text] [Related]
9. A case of resistant pityriasis ribra pilaris responsive to combination acitrentin and ustekinumab.
Cook E; Tran KW; Kollipara S; Tarbox M; Akin R
Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609453
[TBL] [Abstract][Full Text] [Related]
10. Pityriasis rubra pilaris: failure of combination treatment with acitretin and infliximab.
Lu R; George SJ; Hsu S
Dermatol Online J; 2006 May; 12(4):18. PubMed ID: 17083873
[No Abstract] [Full Text] [Related]
11. Successful response of refractory type I adult-onset pityriasis rubra pilaris with ustekinumab and acitretin combination therapy.
Byekova Y; Sami N
J Dermatol; 2015 Aug; 42(8):830-1. PubMed ID: 25982628
[No Abstract] [Full Text] [Related]
12. Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases.
Napolitano M; Lembo L; Fania L; Abeni D; Didona D; Didona B
J Dermatol; 2018 Feb; 45(2):202-206. PubMed ID: 29080273
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for the treatment of adult-onset pityriasis rubra pilaris.
Liao WC; Mutasim DF
Arch Dermatol; 2005 Apr; 141(4):423-5. PubMed ID: 15837858
[No Abstract] [Full Text] [Related]
14. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris.
Bonomo L; Levitt JO
Cutis; 2018 May; 101(5):367-369. PubMed ID: 29894526
[TBL] [Abstract][Full Text] [Related]
15. Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review.
Chandy RJ; Chokshi A; Tan I; Feldman SR
J Cutan Med Surg; 2024; 28(3):269-275. PubMed ID: 38549359
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ustekinumab and guselkumab in treatment refractory pityriasis rubra pilaris: A case series.
Pham JP; Allen N; Smith A
Australas J Dermatol; 2022 Nov; 63(4):522-524. PubMed ID: 36129444
[No Abstract] [Full Text] [Related]
17. Successful treatment of pityriasis rubra pilaris with adalimumab - case report.
Bravo EA; Carrion L; Paucar SM; Mendoza R; Rivera C
Dermatol Online J; 2014 Apr; 20(4):22374. PubMed ID: 24746310
[TBL] [Abstract][Full Text] [Related]
18. Pityriasis rubra pilaris after COVID-19 vaccination: successful treatment with ustekinumab.
Vieira Granja B; Amoedo P; Gomes NP; Costa C; Azevedo F; Magina S
An Bras Dermatol; 2024; 99(4):642-644. PubMed ID: 38653608
[No Abstract] [Full Text] [Related]
19. Successful treatment of TNFα inhibitor-resistant pityriasis rubra pilaris with ixekizumab and acitretin.
Chastagner M; Hoelt P; Kanitakis J; Jullien D; Villani AP
Eur J Dermatol; 2019 Apr; 29(2):218-220. PubMed ID: 30827945
[No Abstract] [Full Text] [Related]
20. Efficacy of ustekinumab after failure of infliximab CT-P13 in a HLA-Cw6-positive patient affected by pityriasis rubra pilaris: monitoring with reflectance confocal microscopy (RCM) and optical coherence tomography (OCT).
Paganelli A; Ciardo S; Odorici G; Pellacani G; Conti A
J Eur Acad Dermatol Venereol; 2017 May; 31(5):e249-e251. PubMed ID: 27739122
[No Abstract] [Full Text] [Related]
[Next] [New Search]
